Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.

Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani HA, Hennessy B, Jansa P, Mehta S, Perchenet L, Pulido T, Rosenberg D, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Wei LJ, Channick R, Benza R.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005095. doi: 10.1161/CIRCOUTCOMES.118.005095.

PMID:
31109190
2.

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.

Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF.

Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.

3.

An insider view on the World Symposium on Pulmonary Hypertension.

Humbert M, Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Lancet Respir Med. 2019 Jun;7(6):484-485. doi: 10.1016/S2213-2600(19)30111-0. Epub 2019 Apr 4. No abstract available.

PMID:
30956061
4.

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.

Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Galiè N.

Eur J Heart Fail. 2019 Mar;21(3):352-359. doi: 10.1002/ejhf.1375. Epub 2019 Jan 11.

5.

An overview of the 6th World Symposium on Pulmonary Hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir J. 2019 Jan 24;53(1). pii: 1802148. doi: 10.1183/13993003.02148-2018. Print 2019 Jan. No abstract available.

6.

Clinical trial design and new therapies for pulmonary arterial hypertension.

Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801908. doi: 10.1183/13993003.01908-2018. Print 2019 Jan.

7.

Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.

Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group.

J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22.

8.

Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.

Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ.

J Heart Lung Transplant. 2018 Dec;37(12):1410-1417. doi: 10.1016/j.healun.2018.07.001. Epub 2018 Sep 9.

PMID:
30209017
9.

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial.

Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G.

PLoS One. 2018 Mar 28;13(3):e0193226. doi: 10.1371/journal.pone.0193226. eCollection 2018.

10.

Overdue to understand anticoagulation in pulmonary arterial hypertension.

Parikh KS, Gray MP, Rubin LJ, Badesch D, Krasuski RA.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217743184. doi: 10.1177/2045893217743184. No abstract available.

11.

Cor Pulmonale Revisited. From Ferrer and Harvey to the Present.

Rubin LJ.

Ann Am Thorac Soc. 2018 Feb;15(Suppl 1):S42-S44. doi: 10.1513/AnnalsATS.201710-772KV.

PMID:
29461887
12.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.

McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N.

J Am Coll Cardiol. 2018 Feb 20;71(7):752-763. doi: 10.1016/j.jacc.2017.12.010.

13.

Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era: Importance of Serial Hemodynamic Measurements.

Rubin LJ.

Circulation. 2018 Feb 13;137(7):705-706. doi: 10.1161/CIRCULATIONAHA.117.031499. No abstract available.

PMID:
29440197
14.

Macitentan in pulmonary hypertension due to left ventricular dysfunction.

Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ.

Eur Respir J. 2018 Feb 7;51(2). pii: 1701886. doi: 10.1183/13993003.01886-2017. Print 2018 Feb.

15.

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.

Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S.

Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. doi: 10.1007/s40256-017-0262-z.

16.

Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.

Chan SY, Rubin LJ.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170094. doi: 10.1183/16000617.0094-2017. Print 2017 Dec 31. Review. Erratum in: Eur Respir Rev. 2018 Jan 24;27(147):.

17.

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study.

Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ.

J Heart Lung Transplant. 2018 Mar;37(3):401-408. doi: 10.1016/j.healun.2017.09.024. Epub 2017 Oct 2.

PMID:
29096938
18.

Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension.

Rubin LJ.

Eur Respir J. 2017 Sep 11;50(3). pii: 1701370. doi: 10.1183/13993003.01370-2017. Print 2017 Sep. No abstract available.

19.

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.

Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM.

Eur Respir J. 2017 Aug 17;50(2). pii: 1602493. doi: 10.1183/13993003.02493-2016. Print 2017 Aug.

20.

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A.

Eur Heart J. 2017 Apr 14;38(15):1147-1155. doi: 10.1093/eurheartj/ehx025.

21.

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24.

22.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

23.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
24.

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.

Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O.

Chest. 2017 Jan;151(1):106-118. doi: 10.1016/j.chest.2016.08.1473. Epub 2016 Sep 23. Erratum in: Chest. 2018 May;153(5):1287.

25.

The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale.

Rubin LJ.

Eur Respir J. 2016 Sep;48(3):617-8. doi: 10.1183/13993003.01333-2016. No abstract available.

26.

Pulmonary Hypertension Overlap Syndromes: A Real Entity?

Ben-Yehuda O, Rubin LJ.

J Am Coll Cardiol. 2016 Jul 26;68(4):379-81. doi: 10.1016/j.jacc.2016.05.045. No abstract available.

27.

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.

Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH 3rd, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ.

Chest. 2016 Jul;150(1):27-34. doi: 10.1016/j.chest.2015.11.005. Epub 2016 Jan 13.

28.

Are Animal Models of Pulmonary Hypertension Relevant to the Clinical Disease?

Rubin LJ.

J Am Coll Cardiol. 2016 May 3;67(17):2047-9. doi: 10.1016/j.jacc.2016.03.002. No abstract available.

29.

Pulmonary Artery Denervation for Pulmonary Artery Hypertension.

Rubin LJ.

JACC Cardiovasc Interv. 2015 Dec 28;8(15):2024-2025. doi: 10.1016/j.jcin.2015.10.022. No abstract available.

30.

Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators.

N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.

31.

Improving patient outcomes in pulmonary hypertension.

Galiè N, McLaughlin VV, Rubin LJ, Simonneau G.

Eur Respir Rev. 2015 Dec;24(138):550-1. doi: 10.1183/16000617.0064-2015. No abstract available.

32.

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.

Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ.

Eur Respir J. 2015 Dec;46(6):1711-20. doi: 10.1183/13993003.00364-2015. Epub 2015 Oct 22.

33.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

34.

Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.

Vachiery JL, Rubin LJ.

Eur Respir J. 2015 Aug;46(2):297-8. doi: 10.1183/13993003.00907-2015. No abstract available.

35.

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.

Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2015 Mar;34(3):338-47. doi: 10.1016/j.healun.2014.12.001. Epub 2014 Dec 12.

36.

[New trial designs and potential therapies for pulmonary artery hypertension].

Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:106-18. Turkish.

37.

[Updated treatment algorithm of pulmonary arterial hypertension].

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:78-94. Turkish.

38.

The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target?

Rubin LJ.

J Am Coll Cardiol. 2015 Feb 24;65(7):681-3. doi: 10.1016/j.jacc.2014.11.049. No abstract available.

39.

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).

Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA.

Eur Respir J. 2015 May;45(5):1303-13. doi: 10.1183/09031936.00090614. Epub 2015 Jan 22.

40.

Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N.

JACC Heart Fail. 2015 Jan;3(1):1-8. doi: 10.1016/j.jchf.2014.07.013. Epub 2014 Nov 11.

41.

New horizons in pulmonary arterial hypertension management.

McLaughlin V, Simonneau G, Galiè N, Rubin LJ.

Eur Respir Rev. 2014 Dec;23(134):408-9. doi: 10.1183/09059180.00007614. No abstract available.

42.

Chronic thromboembolic pulmonary hypertension.

Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ.

Lancet Respir Med. 2014 Jul;2(7):573-82. doi: 10.1016/S2213-2600(14)70089-X. Epub 2014 Jun 2. Review.

PMID:
24898750
43.

Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB; PACES Study Group.

J Heart Lung Transplant. 2014 Jul;33(7):689-97. doi: 10.1016/j.healun.2014.02.019. Epub 2014 Feb 22.

PMID:
24815795
44.

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.

Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ.

Int J Cardiol. 2014 Mar 15;172(2):332-9. doi: 10.1016/j.ijcard.2013.12.179. Epub 2014 Jan 9.

45.

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.

Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V.

Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16.

46.

Macitentan and pulmonary arterial hypertension.

Pulido T, Rubin LJ, Simonneau G.

N Engl J Med. 2014 Jan 2;370(1):82-3. doi: 10.1056/NEJMc1313112. No abstract available.

PMID:
24382071
47.

New trial designs and potential therapies for pulmonary artery hypertension.

Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D82-91. doi: 10.1016/j.jacc.2013.10.026. Review.

48.

Updated treatment algorithm of pulmonary arterial hypertension.

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi: 10.1016/j.jacc.2013.10.031. Review.

49.

Pulsed estrogen therapy prevents post-OVX porcine dura mater microvascular network weakening via a PDGF-BB-dependent mechanism.

Glinskii OV, Huxley VH, Glinskii VV, Rubin LJ, Glinsky VV.

PLoS One. 2013 Dec 9;8(12):e82900. doi: 10.1371/journal.pone.0082900. eCollection 2013.

50.

Riociguat for pulmonary hypertension.

Ghofrani HA, Simonneau G, Rubin LJ; Authors of CHEST-1 and PATENT-1.

N Engl J Med. 2013 Dec 5;369(23):2268. doi: 10.1056/NEJMc1312903. No abstract available.

PMID:
24304056

Supplemental Content

Loading ...
Support Center